Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2640

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2640
---
 uncertainty and are
based on assumptions and estimates which may not prove to be accurate. The estimates and forecasts included in this Annual Report on
Form 10-K relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete
meet the size estimates and growth forecasts included in this Annual Report on Form 10-K, our business may not grow at similar rates,
or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties.

107

We
may engage in strategic transactions, which could impact our liquidity, increase our expenses, and present significant distractions to
our management.

We
may consider engaging in a variety of different business arrangements, including mergers and acquisitions, spin-outs, strategic partnerships,
joint ventures, co-marketing, co-promotion, distributorships, development and co-development, restructurings, divestitures, business
combinations and investments on a global basis. Any such transaction(s) may require us to incur non-recurring or other charges, may increase
our near- and long-term expenditures, grow and expand rapidly putting pressure on current resources and capabilities, and may pose significant
integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. Accordingly,
there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transaction
that we do complete could expose us to liability, delays, and implementation obstacles that could harm our business, financial condition,
operating results, and prospects. We have no current commitment or obligation to enter into any transaction described above other than
ones to which we are already committed.

Risks
Related to Employee Matters

If
we lose key management or scientific personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop
current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market
share and could make us less competitive.

Our
ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to attract and retain
highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, including our scientific and
medical personnel, including Dr. Elias and Dr. Kurtis. The loss of the services of any of our executive officers, other key employees,
and other scientific and medical advisors, and our inability to find suitable replacements